Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Status:
Unknown status
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents
is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the
efficacy of the regimen in patients with relapsed ALL.